Advertisement
Advertisement
XGN
Exagen Inc. Common Stock
3.52
USDSponsored
+0.17
+4.91%
Feb 06, 15:58 UTC -5
Closed
After-Market
3.49
-0.04
-1.11%
XGN Earnings Reports
Positive Surprise Ratio
XGN beat 20 of 25 last estimates.
80%
Next Report
Date of Next Report
Mar 09, 2026
Estimate for Q4 25 (Revenue/ EPS)
$17.13M
/-$0.20
Implied change from Q3 25 (Revenue/ EPS)
-0.67%
/-35.48%
Implied change from Q4 24 (Revenue/ EPS)
+25.44%
/--
Exagen Inc. Common Stock earnings per share and revenue
On Nov 04, 2025, XGN reported earnings of -0.31 USD per share (EPS) for Q3 25, missing the estimate of -0.15 USD, resulting in a -94.85% surprise. Revenue reached 17.24 million, compared to an expected 17.06 million, with a 1.06% difference. The market reacted with a -8.96% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of -0.20 USD, with revenue projected to reach 17.13 million USD, implying an decrease of -35.48% EPS, and decrease of -0.67% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Phibro Animal Health Corporation Class A
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.68
Actual
$0.87
Surprise
+27.30%
Canopy Growth Corporation Common Shares
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.04
Actual
-$0.13
Surprise
-198.00%
Aurora Cannabis Inc. Common Shares
Report Date
Feb 04, 2026 For Q3 26
Estimate
$0.21
Actual
$0.12
Surprise
-42.72%
High Tide Inc. Common Shares
Report Date
Jan 29, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.56
Surprise
0.00%
Stryker Corporation
Report Date
Jan 29, 2026 For Q4 25
Estimate
$4.43
Actual
$4.47
Surprise
+0.69%
Boston Scientific Corp.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.78
Actual
$0.80
Surprise
+1.61%
ResMed Inc.
Report Date
Jan 29, 2026 For Q2 26
Estimate
$2.75
Actual
$2.81
Surprise
+2.15%
GE HealthCare Technologies Inc. Common Stock
Report Date
Feb 04, 2026 For Q4 25
Estimate
$1.42
Actual
$1.44
Surprise
+0.96%
Envista Holdings Corporation Common stock, $0.01 par value per share
Report Date
Feb 05, 2026 For Q4 25
Estimate
$0.32
Actual
$0.38
Surprise
+15.43%
Prestige Consumer Healthcare Inc.
Report Date
Feb 05, 2026 For Q3 26
Estimate
$1.15
Actual
$1.13
Surprise
-1.36%
FAQ
What were Exagen Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Exagen Inc. Common Stock reported EPS of -$0.31, missing estimates by -94.85%, and revenue of $17.24M, 1.06% above expectations.
How did the market react to Exagen Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -8.96%, changed from $11.83 before the earnings release to $10.77 the day after.
When is Exagen Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 09, 2026.
What are the forecasts for Exagen Inc. Common Stock's next earnings report?
Based on 9
analysts, Exagen Inc. Common Stock is expected to report EPS of -$0.20 and revenue of $17.13M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement